Diabetes: Ideglira Improves Achievement of Fasting Blood Glucose and Glycated Hemoglobin Targets
Presented at the 52nd Easd European Diabetes Congress New Data From The Dual ™ V Study – Ideglira, Compared with Insulin Glargine 100 U Dosage Incasse, is 4.5 Times More Likely to Achieve Glycemic Targets, Without Episode of Hypoglycemia or Weight Gain, in Adults with Type 2 Diabetes
Novo Nordisk present at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 1 New Data From the Dual V Study Demstrating that ideglira (Xultophy ®) Allaws, in patients with type 2 diabetes uncontrolled by insulin glargine 100 u therapy (20-50 Units), To Reach the Fasting Blood Glucose Target, Without Hypoglycemic episodes and Weight Gain, more frequently Thanks the dosage of insulin glargine 100 u. IDEGLIRA IS THE FIRST COMMINATION OF A LONG-LASTING ISSUTIN (ISSSIM DEGludEC) and A GLP-1 RECEPTOR Agonist (Liraglutide), in Single Daily Administration, Available in Europe.
The Post-Hoc Analysis of the Phase 3B Dual V Study was conducted by adopting the Fasting Blood Glucose Target of 7.2 mmol/l (130 mg/dl), to better reflect clinical Practice 2 . The Data Showed That Adults Treated with idealra Were 4.5 Times More Likely to Achieve the target Without Confirmed Episode of Hypoglycemia And Weight Gain Compared with Increaseing the dosage of insulin Glargine 100 U (41.4% vs 14.3%; p<0.0001). 1
The Analysis Also Showed that significantly More Adults Achieved the target Glycated Hemoglobin (HBA1C) Less Than 7%, Without Episode of Hypoglycemia and Weight Gain, Regardless of the Baseline HBA Figure1C (Less Than or Equal to 7.5, Between 7.5 and 8.5, or Greater Than 8.5), Again appeared with Incaseing the dosage of insulin glargine 100 u (51 percent vs. 25 percent; 39 percent vs. 11 percent; 32 percent vs. 5 percent; p<0.005). 1
In addition, Both Fasting Blood glucose and glycated Hemoglobin Showed a Significant Reduction as Early As 4, 8, and 12 Weeks After Switching to Ideglira Treatment Compared with Incaseing the dosage of insulin Glargine 100 U, Manifesting Improved Glycemic Control Within A Rapid Time FROM TREATMENT change. 1
“These Analyses from the dual ™ V study indicated that ideglira is effects in Helping patients Achieve Glycemic Control, with Lower Risk of Hypoglycemia And Weight Gain, Compared with Incaseing the dosage of insulin Glargine 100 u, based on targets used in clinical practice , “Said Ildiko Lingvay, Associate Professor of Internal Medicine and Clinical Science At Ut Southwestern Medical Center. “Data Demstrate Improvement in Glycemic Control As Early As Four Weeks After Starting Treatment.”.
IDEGLIRA (XINOPHY ®) is a Single Daily Injection Combination of Insultin Degludec, A Long-Acting Analogue of Basal Insulin, and Liraglutide, Analogue of Human GLP-1. The Maximum Dosage of IDEGLIRA IS 50 Unit Doses, equivalent to 50 Units of Insulin Degludec and 1.8 mg of liraglutide. 3
IDEGLIRA IS Being Evaluated Under the Dual ™ Clinical Development Program, Which Includes 6 Studies Involving More Than 3.850 People With Type 2 Diabetes. Phase 3B Studies Are Still Ongoing. IDEGLIRA RECEIVED MARKETING Authorization from the European Commission on September 18, 2014. 3
Dual ™ V
Dual ™ V is a Phase 3B, 26-Week, Treat-to-Target, Randomized, Open-Label, Multicenter Study conducted in 10 country in 557 patients. Study buy effectiveness and safety of ideglira versus insulin glargine, Both in combination with metformin, in adults with type 2 diabetes not controlled with insulin glargine. The Averal Dose of Insulin Glargine Used Before The Study was 32 Units.
Patient Were Allawed to Add The Maximum Dose of Ideglira (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide) During the course of the study, While no limit was placed on the daily use of insulin glargine. 4
Novo Nordisk is an International Pharmaceutical Company with More Than 90 Years of Research, Innovation and Leadership in the Treatment of Diabetes. This Wealth of Knowledge Has Given Us The Knowledge That We Can Help Others Afflicted With Serious Chronic Diseases: Hemophilia, Growth Disorders, And Obesity ’. Based in Denmark, Novo Nordisk Has Approximatelo 40.300 Employees in 75 Countries and Markets Its Products in More Than 180 Countries. For More Information, Visit